| Code | Description | Claims | Beneficiaries | Total Paid |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
265,812 |
249,534 |
$15.38M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
55,841 |
55,035 |
$5.24M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
47,805 |
44,464 |
$4.18M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
36,637 |
34,667 |
$3.14M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
28,969 |
28,623 |
$2.74M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
12,667 |
12,553 |
$1.32M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
7,146 |
6,969 |
$987K |
| 90686 |
|
60,816 |
60,281 |
$859K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
18,344 |
17,739 |
$688K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
23,024 |
22,723 |
$532K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
11,306 |
11,056 |
$524K |
| 90670 |
|
26,841 |
26,507 |
$415K |
| 90648 |
|
27,938 |
27,574 |
$406K |
| 90723 |
|
19,411 |
19,113 |
$285K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,364 |
6,213 |
$236K |
| 96127 |
|
3,919 |
3,865 |
$197K |
| 90680 |
|
13,073 |
12,897 |
$194K |
| 90677 |
|
4,535 |
4,414 |
$182K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,319 |
1,243 |
$176K |
| 90633 |
|
10,633 |
10,484 |
$151K |
| 0071A |
|
2,645 |
2,635 |
$100K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,037 |
1,018 |
$99K |
| 99460 |
|
892 |
870 |
$93K |
| 0072A |
|
2,309 |
2,303 |
$88K |
| 90651 |
|
4,225 |
4,193 |
$74K |
| 92551 |
|
4,792 |
4,743 |
$72K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
854 |
831 |
$61K |
| 80061 |
Lipid panel |
3,792 |
3,653 |
$54K |
| 90656 |
|
4,822 |
4,809 |
$47K |
| 90734 |
|
2,534 |
2,506 |
$44K |
| 0111A |
|
1,158 |
1,154 |
$43K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
849 |
828 |
$43K |
| 0002A |
|
1,108 |
1,106 |
$42K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,909 |
2,895 |
$39K |
| 0124A |
|
966 |
946 |
$36K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
454 |
445 |
$36K |
| 85018 |
|
14,052 |
13,800 |
$36K |
| 0001A |
|
917 |
916 |
$35K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,061 |
2,021 |
$31K |
| 0154A |
|
802 |
792 |
$30K |
| 90710 |
|
1,743 |
1,718 |
$29K |
| 0112A |
|
764 |
755 |
$29K |
| 90696 |
|
1,597 |
1,581 |
$25K |
| 90681 |
|
1,711 |
1,694 |
$24K |
| 0074A |
|
610 |
608 |
$23K |
| 36415 |
Collection of venous blood by venipuncture |
6,296 |
5,997 |
$23K |
| 90672 |
|
1,235 |
1,225 |
$22K |
| 0054A |
|
583 |
577 |
$22K |
| 99188 |
|
1,058 |
1,039 |
$20K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
152 |
152 |
$19K |
| Q3014 |
Telehealth originating site facility fee |
959 |
942 |
$19K |
| 90715 |
|
950 |
942 |
$15K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
270 |
265 |
$14K |
| 91321 |
|
697 |
695 |
$14K |
| 92583 |
|
437 |
432 |
$13K |
| 94010 |
|
291 |
289 |
$12K |
| 99173 |
|
5,346 |
5,275 |
$11K |
| 90700 |
|
720 |
708 |
$10K |
| 90716 |
|
617 |
615 |
$10K |
| 90707 |
|
608 |
606 |
$10K |
| 92552 |
|
709 |
700 |
$10K |
| 90461 |
|
4,608 |
4,527 |
$10K |
| 0164A |
|
279 |
274 |
$10K |
| 0004A |
|
248 |
247 |
$9K |
| 90620 |
|
245 |
243 |
$7K |
| 0052A |
|
179 |
178 |
$7K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
141 |
138 |
$6K |
| 87081 |
|
798 |
781 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
42 |
41 |
$5K |
| 0051A |
|
137 |
137 |
$5K |
| 91322 |
|
225 |
224 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
225 |
220 |
$4K |
| 99177 |
|
539 |
531 |
$4K |
| 99383 |
|
32 |
32 |
$4K |
| 99000 |
|
9,030 |
8,740 |
$3K |
| 90480 |
|
178 |
174 |
$3K |
| 90685 |
|
239 |
239 |
$3K |
| 83655 |
|
152 |
147 |
$2K |
| 0142A |
|
80 |
76 |
$2K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
1,041 |
891 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,210 |
1,168 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
121 |
107 |
$1K |
| 0141A |
|
49 |
46 |
$1K |
| 36416 |
|
24,148 |
23,557 |
$1K |
| 0144A |
|
41 |
41 |
$1K |
| 81002 |
|
368 |
349 |
$1K |
| D1208 |
Topical application of fluoride, excluding varnish |
93 |
93 |
$990.15 |
| 94375 |
|
12 |
12 |
$791.68 |
| 90660 |
|
79 |
79 |
$708.56 |
| 54150 |
|
12 |
12 |
$690.89 |
| 99462 |
|
14 |
12 |
$660.59 |
| 94664 |
|
25 |
25 |
$578.44 |
| 99429 |
|
20 |
12 |
$481.47 |
| 90688 |
|
856 |
848 |
$473.38 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
77 |
77 |
$430.50 |
| 90381 |
|
35 |
35 |
$384.89 |
| 69209 |
|
28 |
27 |
$342.36 |
| 81025 |
|
32 |
30 |
$256.67 |
| 88720 |
|
40 |
37 |
$203.84 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
14 |
12 |
$183.89 |
| 86580 |
|
12 |
12 |
$92.78 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
14 |
12 |
$88.55 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
16 |
16 |
$2.83 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
41 |
39 |
$0.50 |
| 91315 |
|
319 |
315 |
$0.00 |
| 91316 |
|
107 |
104 |
$0.00 |
| 91307 |
|
2,140 |
2,035 |
$0.00 |
| 91305 |
|
342 |
327 |
$0.00 |
| 94760 |
|
15 |
13 |
$0.00 |
| 91300 |
|
468 |
452 |
$0.00 |
| 91312 |
|
366 |
342 |
$0.00 |
| 91311 |
|
759 |
747 |
$0.00 |